Jiecheng Medical Technology

Jiecheng Medical Technology is a prominent medical device company specializing in the development of innovative transcatheter heart valve replacement systems. The company is best known for its proprietary J-Valve system, a transcatheter aortic valve replacement (TAVR) technology designed to treat both aortic stenosis and aortic regurgitation through a minimally invasive approach. Notably, the J-Valve system was the first TAVR device approved by the NMPA in China for the treatment of pure aortic regurgitation, addressing a significant unmet clinical need. In 2022, Jiecheng Medical was acquired by Venus Medtech, a leader in China's structural heart disease market, to integrate the J-Valve technology into a broader cardiovascular portfolio. The company continues to advance its product line, including the development of next-generation transfemoral delivery systems to improve patient outcomes.